Show simple item record

dc.contributor.authorden Boer, Margriet Leontine
dc.contributor.authorAlvar, Jorge
dc.contributor.authorDavidson, Robert N
dc.contributor.authorRitmeijer, Koert
dc.contributor.authorBalasegaram, Manica
dc.date.accessioned2011-04-07T16:07:15Z
dc.date.available2011-04-07T16:07:15Z
dc.date.issued2009-09-01
dc.date.submitted2010-10-15
dc.identifier.citationExpert Opin Emerg Drugs2009;14 (3):395-410en
dc.identifier.issn1744-7623
dc.identifier.pmid19708817
dc.identifier.doi10.1517/14728210903153862
dc.identifier.urihttp://hdl.handle.net/10144/127729
dc.description.abstractBACKGROUND: Visceral leishmaniasis (VL) is one of the most neglected parasitic diseases causing large scale mortality and morbidity among the poorest of the poor in the Indian subcontinent and Africa. OBJECTIVE: This review aims to describe the potential and the (lack of) current impact of newly developed treatments on the control of VL. It describes how the problem of an empty research pipeline is addressed, and discusses the emerging threat of incurable HIV/VL coinfection. METHODS: The literature was searched for drugs used in VL. CONCLUSION: Research and development of VL drugs has received a financial boost but no new drugs are expected in the next 5 years. Only three new and highly effective treatments have been licensed in the past 10 years. These remain, however, largely inaccessible as VL control programs in the developing world are lacking. This is deserving of immediate and urgent attention, especially in the context of the rapidly expanding HIV/VL coinfection.
dc.language.isoenen
dc.relation.urlhttp://informahealthcare.com/doi/abs/10.1517/14728210903153862en
dc.rightsArchived with thanks to Expert Opinion on Emerging Drugsen
dc.subject.meshAfricaen
dc.subject.meshAnimalsen
dc.subject.meshAntiprotozoal Agentsen
dc.subject.meshDeveloping Countriesen
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshHumansen
dc.subject.meshLeishmaniaen
dc.subject.meshLeishmaniasis, Visceralen
dc.titleDevelopments in the treatment of visceral leishmaniasisen
dc.typeArticleen
dc.contributor.departmentMedecins Sans Frontieres, Amsterdam, The Netherlandsen
dc.identifier.journalExpert Opinion on Emerging Drugsen
refterms.dateFOA2019-03-04T08:40:48Z
html.description.abstractBACKGROUND: Visceral leishmaniasis (VL) is one of the most neglected parasitic diseases causing large scale mortality and morbidity among the poorest of the poor in the Indian subcontinent and Africa. OBJECTIVE: This review aims to describe the potential and the (lack of) current impact of newly developed treatments on the control of VL. It describes how the problem of an empty research pipeline is addressed, and discusses the emerging threat of incurable HIV/VL coinfection. METHODS: The literature was searched for drugs used in VL. CONCLUSION: Research and development of VL drugs has received a financial boost but no new drugs are expected in the next 5 years. Only three new and highly effective treatments have been licensed in the past 10 years. These remain, however, largely inaccessible as VL control programs in the developing world are lacking. This is deserving of immediate and urgent attention, especially in the context of the rapidly expanding HIV/VL coinfection.


Files in this item

Thumbnail
Name:
090901_denBoer_VL-drug-devel_E ...
Size:
1.756Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record